Crescent Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $35.3M | $40.0M |
| FY2017 | — | $119.7M | $123.9M |
| FY2018 | — | $205.5M | $209.9M |
| FY2019 | — | $154.2M | $158.2M |
| FY2020 | — | $128.2M | $137.0M |
| FY2021 | — | $81.6M | $90.3M |
| FY2022 | — | $42.9M | $47.9M |
| FY2023 | — | $38.4M | $41.8M |
| FY2024 | — | $0 | $0 |
| FY2025 | — | $203.0M | $213.2M |